Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.

RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%

In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs

JB Pharma ranks 23 in Indian pharma market

JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens

Essential Pharma progress in its ESG performance

The company now exceeds the sector benchmark for its overall ESG rating and for all three measures

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine

Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.